Abstract
An evaluation of risks versus benefits from new products should be encouraged, even when dealing with agents which may cause cancer or malformations in laboratory animals, because there is evidence that safety thresholds exist even for such exposures. However, it is not easy to describe risk and benefit in comparable terms when they may involve generations to come and events in the future.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BARNES J. M., DENZ F. A. Experimental methods used in determining chronic toxicity; a critical review. Pharmacol Rev. 1954 Jun;6(2):191–242. [PubMed] [Google Scholar]
- Cleaver J. E. Defective repair replication of DNA in xeroderma pigmentosum. Nature. 1968 May 18;218(5142):652–656. doi: 10.1038/218652a0. [DOI] [PubMed] [Google Scholar]
- Fahey J. L. Cancer in the immunosuppressed patient. Ann Intern Med. 1971 Aug;75(2):310–312. doi: 10.7326/0003-4819-75-2-310. [DOI] [PubMed] [Google Scholar]
- Roe F. J., Carter R. L., Mitchley B. C., Peto R., Hecker E. On the persistence of tumour initiation and the acceleration of tumour progression in mouse skin tumorigenesis. Int J Cancer. 1972 Mar 15;9(2):264–273. doi: 10.1002/ijc.2910090204. [DOI] [PubMed] [Google Scholar]
- Selikoff I. J., Hammond E. C., Churg J. Asbestos exposure, smoking, and neoplasia. JAMA. 1968 Apr 8;204(2):106–112. [PubMed] [Google Scholar]
- WITKIN E. M. Modification of mutagenesis initiated by ultraviolet light through postteatment of bacteria with basic dyes. J Cell Comp Physiol. 1961 Dec;58(3):135–144. doi: 10.1002/jcp.1030580413. [DOI] [PubMed] [Google Scholar]